CFH and hemolytic-uremic syndrome: More rarely, 5 to 10% of patients have autoantibodies against factor H. The remaining 40 to 50% of patients with primary HUS do not have any rare variants nor autoantibodies evidenced, but this does not exclude the possibility of other complement regulation abnormalities in the pathophysiology.